-
公开(公告)号：US09663558B2
公开(公告)日：2017-05-30
申请号：US14904077
申请日：2014-07-10
Applicant: GE Healthcare Bio-Sciences AB
Inventor： Mats Ander , Goran Bauren , Tomas Bjorkman , Gustav Rodrigo
IPC: C07K14/31 , C07K1/22 , B01D15/38 , B01J20/286 , B01J20/32 , C07K14/745 , C07K16/00
CPC classification number: C07K14/31 , B01D15/3809 , B01J20/286 , B01J20/3204 , B01J20/3212 , B01J20/3219 , B01J20/3274 , C07K1/22 , C07K14/745 , C07K16/00
Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.
-
公开(公告)号：US20160159857A1
公开(公告)日：2016-06-09
申请号：US14961164
申请日：2015-12-07
Applicant: GE Healthcare Bio-Sciences AB
Inventor： Gustav Rodrigo , Mats Ander , Göran Baurén , Tomas Björkman
CPC classification number: C07K14/31 , B01D15/3809 , B01J20/286 , B01J20/3204 , B01J20/3212 , B01J20/3219 , B01J20/3274 , C07K1/22 , C07K14/745 , C07K16/00
Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.
Abstract translation: 本发明公开了一种具有改善的碱稳定性的多肽，该多肽包含如SEQ ID NO：1或SEQ ID NO：2或蛋白Z所定义的葡萄球菌蛋白A（SpA）的B或C结构域的突变体，如 SEQ ID NO 3至少包含其中位置9处的谷氨酰胺残基突变为色氨酸，亮氨酸，谷氨酸，缬氨酸或赖氨酸的突变。 本发明还公开了多肽的多聚体，以及包含多聚体或多肽的分离基质。
-
公开(公告)号：US20150299248A1
公开(公告)日：2015-10-22
申请号：US14441129
申请日：2013-11-11
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Jean-Luc Maloisel , Gustav Rodrigo , Bjorn Noren , Virendra Kumbhar
IPC: C07K1/16 , C07K1/36 , B01J20/289 , B01J20/26 , B01J20/28
CPC classification number: C07K1/165 , B01D15/3847 , B01D15/3885 , B01J20/265 , B01J20/28016 , B01J20/289 , B01J20/3204 , B01J20/3208 , B01J20/3219 , B01J20/3251 , B01J20/3253 , B01J20/3255 , B01J20/3285 , B01J41/20 , B01J2220/80 , C07K1/36 , G01N33/544 , B01D15/363 , B01D15/327
Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five- or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.
Abstract translation: 本发明公开了一种分离基质，其包含固定在载体上的式R1-L1-N（R3）-L2-R定义的多个分离配体，其中R1是五或六元的取代或非取代的 取代的环结构或羟乙基或羟丙基; L1是亚甲基或共价键; R2是五或六元，取代或未取代的环结构; L2是亚甲基或共价键; R3是甲基; 并且其中如果R 1是羟乙基并且L 1是共价键，则R 2是取代的芳环结构或取代或未取代的脂族环结构。
-
Patent Agency Ranking
4.发明申请Chromatography Ligand Comprising Domain C From Staphylococcus Aureus Protein A For Antibody Isolation 有权色谱配体包含来自金黄色葡萄球菌蛋白A的抗体分离区域C公开(公告)号：US20160200797A1
公开(公告)日：2016-07-14
申请号：US15063471
申请日：2016-03-07
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Martin Hall , Sture Larsson , Andreas Muranyi , Gustav Rodrigo , Jinyu Zou , Per-Mikael Aberg
CPC classification number: B01J20/24 , B01D15/3809 , B01J20/28019 , B01J20/285 , B01J20/286 , B01J20/289 , B01J20/3212 , B01J20/3219 , B01J20/3274 , B01J20/3293 , B01J2220/52 , B01J2220/54 , C07K1/22 , C07K14/31 , C07K16/00 , C07K17/00 , C07K17/10 , C07K2317/55
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
Abstract translation: 本发明涉及一种色谱配体，其包含来自葡萄球菌蛋白A（SpA）的结构域C，或其功能片段或变体。 色谱配体具有在现场（CIP）条件下耐受苛刻清洁的有利能力，并且能够结合抗体的Fab片段。 配体可以具有末端偶联基团，例如精氨酸或半胱氨酸，以促进其与不溶性载体例如珠粒或膜的偶联。 本发明还涉及在分离抗体中使用配体的方法以及可以包括洗涤步骤和/或用碱再生的纯化方案。
-
5.发明授权Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation 有权包含来自金黄色葡萄球菌蛋白A的结构域C的色谱配体用于抗体分离公开(公告)号：US09290549B2
公开(公告)日：2016-03-22
申请号：US14164519
申请日：2014-01-27
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Martin Hall , Sture Larsson , Andreas Muranyi , Gustav Rodrigo , Jinyu Zou , Per-Mikael Aberg
CPC classification number: B01J20/24 , B01D15/3809 , B01J20/28019 , B01J20/285 , B01J20/286 , B01J20/289 , B01J20/3212 , B01J20/3219 , B01J20/3274 , B01J20/3293 , B01J2220/52 , B01J2220/54 , C07K1/22 , C07K14/31 , C07K16/00 , C07K17/00 , C07K17/10 , C07K2317/55
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
Abstract translation: 本发明涉及一种色谱配体，其包含来自葡萄球菌蛋白A（SpA）的结构域C，或其功能片段或变体。 色谱配体具有在现场（CIP）条件下耐受苛刻清洁的有利能力，并且能够结合抗体的Fab片段。 配体可以具有末端偶联基团，例如精氨酸或半胱氨酸，以促进其与不溶性载体例如珠粒或膜的偶联。 本发明还涉及在分离抗体中使用配体的方法以及可以包括洗涤步骤和/或用碱再生的纯化方案。
-
公开(公告)号：US20160159855A1
公开(公告)日：2016-06-09
申请号：US14903837
申请日：2014-07-08
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Gustav Rodrigo , Mats Ander , Tomas BJORKMAN , Goran Bauren
IPC: C07K1/22 , C07K14/745 , C07K16/00 , C07K14/31
CPC classification number: C07K14/31 , B01D15/3809 , B01J20/286 , B01J20/3204 , B01J20/3212 , B01J20/3219 , B01J20/3274 , C07K1/22 , C07K14/745 , C07K16/00
Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
Abstract translation: 具有改善的碱稳定性的多肽，所述多肽包含SEQ ID NO 1或SEQ ID NO 2所规定的葡萄球菌蛋白A的B或C结构域或如SEQ ID NO 3所定义的蛋白Z的突变体，其中 至少第9位的谷氨酰胺残基已被突变为除天冬酰胺之外的氨基酸。 本发明还公开了所述多肽的多聚体，以及包含多聚体或多肽的分离基质。
-
公开(公告)号：US20150133618A1
公开(公告)日：2015-05-14
申请号：US14396207
申请日：2013-04-22
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Jesper Hanssen , Gustav Rodrigo , Tobias E Soderman
CPC classification number: B01J39/26 , B01D15/1864 , B01D15/34 , B01D15/361 , B01D15/362 , B01D15/3809 , B01J20/24 , B01J20/261 , B01J20/265 , B01J20/267 , B01J20/28014 , B01J20/28033 , B01J20/286 , B01J20/289 , B01J20/3085 , B01J20/3212 , B01J20/3278 , B01J20/3282 , B01J2220/80 , C07H1/08 , C07K1/22 , G01N2030/8827 , Y02P20/582
Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2═CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.
Abstract translation: 本发明公开了一种从液体中的至少一种其它组分分离生物分子的方法，包括使所述液体与包含固体支持物和与所述固体支持物结合的聚合物链的分离基质接触的步骤。 聚合物链包含衍生自结构为CH 2 = CH-L-X的第一单体的单元，其中L为共价键或包含2-6个碳原子的烷基醚或羟基取代的烷基醚链，X为磺酸盐或膦酸酯基团。
-
公开(公告)号：US20150080554A1
公开(公告)日：2015-03-19
申请号：US14385336
申请日：2013-03-26
Applicant: GE HEALTHCARE BIO-SCIENCES AB
Inventor： Mats Ander , Goran Bauren , Tomas Bjorkman , Per-Mikael Aberg , Gustav Rodrigo
IPC: C07K16/00 , C07K14/31 , G01N33/68 , B01J20/291
CPC classification number: C07K16/00 , B01D15/3809 , B01J20/286 , B01J20/291 , B01J20/3212 , B01J20/3219 , B01J20/3274 , B01J2220/80 , C07K1/22 , C07K14/31 , G01N33/6854
Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.
Abstract translation: 本发明公开了一种免疫球蛋白结合蛋白，其包含葡萄球菌蛋白A（E，D，A，B，C）或蛋白Z或其功能变体的一个或多个突变的免疫球蛋白结合结构域（单体），其中至少一个 一个或多个突变单体，在对应于蛋白A或蛋白Z的B结构域的H18的位置处的天冬酰胺或组氨酸已被缺失或被不是脯氨酸或天冬酰胺的第一氨基酸残基取代，并且其中，如果 第57位的氨基酸残基是脯氨酸，28位的氨基酸残基是天冬酰胺，则相应于蛋白A的B结构域或蛋白Z的H18位置的氨基酸残基不是丝氨酸，苏氨酸或赖氨酸。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.017 seconds)
